Dr. Hardwick has 17 years experience in biomedical process and product development. Most recently he served as Director, Cell Processing at Xcyte Therapies, Inc., a Seattle-based biotechnology company focused on cellular therapies. In this capacity, he directed the development and documentation of a closed-system, large-scale process for preparing, culturing, harvesting and shipping of patient T-cells for use in adoptive immunotherapy protocols. From 1983 to 1998 Dr. Hardwick held several positions at Baxter Healthcare Corporation and was, most recently, Associate Director, Cell Processing Systems in the Immunotherapy Division. In this position he started or refined large-scale blood cell processes, involving cell collection, purification, transduction, expansion and storage, to support gene therapy or cell therapy clinical trials in the U.S., Europe and Japan. He also served as Senior Principal Engineer and Engineering Manager in the Immunotherapy Division and as Principal Engineer in the Fenwal Division of Baxter Healthcare Corporation. He holds a Ph.D. in Chemical Engineering from Rice University, a M.S. in Chemical Engineering from the University of Illinois and a B.S. in Chemical Engineering from Washington University.